HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Access To US Consumers Means More False Claims For COVID-19 Than Other Health Dangers

Executive Summary

While types of unsupported claims were no different than those advertisers made when US was hit it by other widespread health emergencies, digital capabilities made advertisers’ response to COVID-19 different, says Rich Cleland, FTC Consumer Protection Bureau attorney.

You may also be interested in...



FTC Expands Dietary Supplement Advertising Guidance To All Products Making Health-Related Claims

The Federal Trade Commission’s Health Products Compliance Guidance, published 20 December, expands the agency’s focus from dietary supplements to all products making health-related claims, providing the first update in 25 years on the FTC’s thinking on clear and conspicuous disclosures and competent and reliable scientific evidence.

False Treatment Claims Still A COVID-19 Symptom: FTC Files Complaint Against California Firm

FTC files complaint alleging Precision Patient Outcomes marketed a supplement as a treatment to mitigate the effects of COVID-19 after agency let the firm know it considered the claims false advertising.

Michigan Firm’s Nasal Spray Neither A COVID-19 Treatment Nor For Nasal Use

CofixRx and Sensory Cloud are latest OTC nasal spray marketers FDA warned about fraudulent COVID-19 claims. While the others’ violations were limited to violative claims, CofixRx also warned the active ingredient in its spray is limited to topical use.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel